PMID- 37885115
OWN - NLM
STAT- MEDLINE
DCOM- 20240222
LR  - 20240222
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 24
IP  - 6
DP  - 2024
TI  - Liraglutide and Liver Injury: Rare Case Report with Literature Review.
PG  - 725-729
LID - 10.2174/0118715303180615231011053011 [doi]
AB  - BACKGROUND: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist 
      used for the treatment of type 2 diabetes mellitus (T2DM). So far, few severe 
      side effects have been reported for it. CASE PRESENTATION: A 41-year-old woman 
      was admitted to the Emergency Room with diffuse abdominal pain. The patient had a 
      known case of T2DM, fatty liver disease, and hypertension and was treated with 
      Metformin, Liraglutide, and Losartan. Her liver functional test (LFT) was 
      consistent with hepatocellular injury; however, laboratory tests and abdominal 
      ultrasound were used to rule out autoimmune hepatitis. Due to concerns for 
      drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl 
      cysteine was prescribed. On the fifth day of hospitalization, the patient's 
      symptoms resolved and his LFT started to decrease on the sixth day after 2 
      months, the patient's liver enzyme levels returned to normal. CONCLUSION: 
      Liraglutide is one of the most important drugs in the treatment of T2DM.The most 
      common side effects of this drug are constipation, nausea, vomiting, diarrhea, 
      indigestion, and loss of appetite. In rare cases, symptoms of thyroid cancer, 
      pancreatitis, and hypoglycemia have been reported, however, DILL is one of the 
      extremely rare side effect of Liraglutide. It is important to increase the 
      awareness of physicians about the liver injury of Liraglutide.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Salehi, Amir Mohammad
AU  - Salehi AM
AUID- ORCID: 0000-0002-1724-6432
AD  - Student Research Committee, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Hasanzarrini, Maryam
AU  - Hasanzarrini M
AUID- ORCID: 0000-0003-1851-4408
AD  - Clinical Research Development Unit of Shahid Beheshti Hospital, Hamadan 
      University of Medical Sciences, Hamadan, Iran.
FAU - Salehi, Hossain
AU  - Salehi H
AUID- ORCID: 0000-0002-6257-8217
AD  - Gastroenterology Ward, Farheekhtegan Hospital, Islamic Azad University of Medical 
      Sciences, Tehran, Iran.
FAU - Jenabi, Ensiyeh
AU  - Jenabi E
AUID- ORCID: 0000-0002-4536-0814
AD  - Autism Spectrum Disorders Research Center, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
LA  - eng
PT  - Case Reports
PT  - Review
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 839I73S42A (Liraglutide)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Humans
MH  - Female
MH  - Adult
MH  - *Liraglutide/adverse effects
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy/chemically induced
MH  - Hypoglycemic Agents/adverse effects
MH  - Glucagon-Like Peptide 1
MH  - Liver
OTO - NOTNLM
OT  - Drug-induced liver injury
OT  - GLP-1
OT  - LFT
OT  - Liraglutide
OT  - Type 2 diabetes mellitus
OT  - diarrhea
OT  - hypoglycemia.
EDAT- 2023/10/27 06:42
MHDA- 2024/02/22 06:42
CRDT- 2023/10/27 00:43
PHST- 2023/04/18 00:00 [received]
PHST- 2023/08/08 00:00 [revised]
PHST- 2023/09/15 00:00 [accepted]
PHST- 2024/02/22 06:42 [medline]
PHST- 2023/10/27 06:42 [pubmed]
PHST- 2023/10/27 00:43 [entrez]
AID - EMIDDT-EPUB-135577 [pii]
AID - 10.2174/0118715303180615231011053011 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2024;24(6):725-729. doi: 
      10.2174/0118715303180615231011053011.